Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Evangelos Stelios Gragoudas, M.D.

Co-Author

This page shows the publications co-authored by Evangelos Gragoudas and Demetrios Vavvas.
Connection Strength

2.879
  1. Posterior uveal melanoma in young patients treated with proton beam therapy. Retina. 2010 Sep; 30(8):1267-71.
    View in: PubMed
    Score: 0.470
  2. Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin. Invest Ophthalmol Vis Sci. 2021 Apr 01; 62(4):3.
    View in: PubMed
    Score: 0.245
  3. Reply. Ophthalmol Retina. 2021 03; 5(3):e4.
    View in: PubMed
    Score: 0.243
  4. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2020 12; 4(12):1138-1145.
    View in: PubMed
    Score: 0.222
  5. Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration. Sci Rep. 2018 01 11; 8(1):461.
    View in: PubMed
    Score: 0.196
  6. Verteporfin inhibits growth of human glioma in vitro without light activation. Sci Rep. 2017 08 08; 7(1):7602.
    View in: PubMed
    Score: 0.190
  7. Verteporfin-induced formation of protein cross-linked oligomers and high molecular weight complexes is mediated by light and leads to cell toxicity. Sci Rep. 2017 04 21; 7:46581.
    View in: PubMed
    Score: 0.186
  8. Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. EBioMedicine. 2016 Mar; 5:198-203.
    View in: PubMed
    Score: 0.171
  9. Effects of metformin on retinoblastoma growth in vitro and in vivo. Int J Oncol. 2014 Dec; 45(6):2311-24.
    View in: PubMed
    Score: 0.155
  10. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014 Jul; 124:67-73.
    View in: PubMed
    Score: 0.152
  11. Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. Invest Ophthalmol Vis Sci. 2014 Apr 29; 55(7):4175-85.
    View in: PubMed
    Score: 0.151
  12. Aminoimidazole carboxamide ribonucleotide (AICAR) inhibits the growth of retinoblastoma in vivo by decreasing angiogenesis and inducing apoptosis. PLoS One. 2013; 8(1):e52852.
    View in: PubMed
    Score: 0.138
  13. Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J. 2010 Aug; 24(8):2620-30.
    View in: PubMed
    Score: 0.114
  14. A novel nonradioactive method to evaluate vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci. 2010 Mar; 51(3):1677-82.
    View in: PubMed
    Score: 0.111
  15. Preface. Int Ophthalmol Clin. 2004; 44(3):xiii.
    View in: PubMed
    Score: 0.074
  16. In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011 Jun 01; 52(6):3880-7.
    View in: PubMed
    Score: 0.031
  17. Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. PLoS One. 2011 Apr 29; 6(4):e18864.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.